Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Multi Center, Open Label, First-in-human, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-tumors Efficacy of the Glyco-humanized Polyclonal Antibody XON7 in Patients With Advanced or Metastatic Solid Tumors

NCT06154291 is registered in ClinicalTrials.gov with Xenothera SAS as lead sponsor.

NCT NCT06154291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06154291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Multi Center, Open Label, First-in-human, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-tumors Efficacy of the Glyco-humanized Polyclonal Antibody XON7 in Patients With Advanced or Metastatic Solid Tumors
Lead sponsor
Xenothera SAS
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 14, 2023
Completion date
November 30, 2027
Enrollment
255 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic cancer